Selecting appropriate treatment for breast cancer is guided by molecular subtypes and clinical characteristics. Here, the authors show that their AI-based approach, which integrates digital pathology images and clinical data, demonstrates robust accuracy in predicting the risk of cancer recurrence across major molecular breast cancer subtypes, including triple negative breast cancer.
- Jan Witowski
- Ken G. Zeng
- Krzysztof J. Geras